Back to news

iRhythm Announces $100 Million Accelerated Share Repurchase Agreement

Globe Newswire•17/11/2026•16:35 ET
0

Key Highlights

  • ➤iRhythm (IRTC) enters $100 million accelerated share repurchase agreement
  • ➤iRhythm will initially receive approximately 80% of expected repurchased shares
  • ➤Final ASR settlement is expected no later than the first quarter of 2027
  • ➤Approximately $100 million remains under iRhythm’s existing repurchase authorization

SAN FRANCISCO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association (JPMorgan) for $100 million of its common stock, as part of its previously announced $200 million share repurchase authorization.

Under the terms of the ASR, iRhythm will make an initial payment of $100 million to JPMorgan and receive an initial delivery of shares representing approximately 80% of the total number of shares expected to be repurchased under the ASR. The total number of shares that iRhythm will ultimately repurchase under the ASR will be determined based on the volume-weighted average price of the company's common stock during the term of the ASR, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreement. Final settlement of the ASR is expected to occur no later than the first quarter of 2027. Following completion of the ASR, iRhythm will have approximately $100 million remaining available under its outstanding share repurchase authorization.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in